On June 18, 2025, the U.S. Food and Drug Administration (FDA) officially approved Yeztugo®—the brand name for lenacapavir, developed by Gilead Sciences—as the world’s first and only biannual injectable PrEP (Pre-Exposure Prophylaxis) for HIV prevention. This marks a major milestone in medical advancement that has drawn global attention. The approval is based on international clinical
